A further 17 people out of the 60 volunteers participating in the first phase of human trials to develop Nanocovax, a locally-produced novel coronavirus (COVID-19) vaccine, received their vaccine shots on December 22 at the Military Medical Academy.
The first phase of the clinical trial has been divided into three stages, with 20 people for each stage being administered doses ranging from 25mcg to 50mcg and then up to 75 mcg.
According to experts conducting the trials, if the results are reported to be safe among the first group after three days, the second group will receive a shot of 50 mcg, with all of their identities being kept confidential.
This comes after human trials for the vaccine got underway with the first three volunteers, including two men and women, receiving the first dose of 25 mcg on December 17. At present, their health remains in a stable condition and they are being strictly monitored at their places of residence.
Each of the volunteers received two doses of the vaccine intramuscularly, with the interval between the doses being 28 days. Each volunteer will be placed under strict observation for a 56-day period in an effort to assess the vaccine’s safety, whilst they will also be monitored for six months after receiving their first dose.
The clinical trial process on humans to develop the Nanocovax vaccine will consist of three stages, with the first phase being implemented between December to February, 2021, in Hanoi.
This article was originally published on Vietnamnet
Related
Source: Vietnam Insider